Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

Anteris Technologies announced it has received full regulatory clearance from Germany's BfArM to initiate the PARADIGM Trial for its DurAVR Transcatheter Heart Valve in patients with severe aortic stenosis. The clearance enables patient recruitment at leading German centers and strengthens the trial's European expansion, as Germany represents Europe's largest TAVR market with extensive clinical infrastructure.